A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate
Abstract
The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-191. We employed the live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express the prefusion form of the SARS-CoV-2 Spike antigen. In mice, the vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response. In a stringent hamster SARS-CoV-2 challenge model2, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (13161)
- Bioengineering (10015)
- Bioinformatics (32055)
- Biophysics (16525)
- Cancer Biology (13605)
- Cell Biology (19330)
- Clinical Trials (138)
- Developmental Biology (10449)
- Ecology (15515)
- Epidemiology (2067)
- Evolutionary Biology (19803)
- Genetics (13105)
- Genomics (18140)
- Immunology (13252)
- Microbiology (30981)
- Molecular Biology (12910)
- Neuroscience (67668)
- Paleontology (496)
- Pathology (2088)
- Pharmacology and Toxicology (3615)
- Physiology (5635)
- Plant Biology (11612)
- Synthetic Biology (3237)
- Systems Biology (7927)
- Zoology (1794)